Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors

In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way both defining different inclusion criteria regardin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Comput Struct Biotechnol J
Päätekijät: Heydt, Carina, Becher, Ann-Kathrin, Wagener-Ryczek, Svenja, Ball, Markus, Schultheis, Anne M., Schallenberg, Simon, Rüsseler, Vanessa, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Research Network of Computational and Structural Biotechnology 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861603/
https://ncbi.nlm.nih.gov/pubmed/31762957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.csbj.2019.09.003
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia